Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estradiol Routes and Coagulation in Transgender Women
NCT05387577Phase 1Terminated
- Sponsor
- Medical College of Wisconsin
- Start
- Dec 2021
- Primary completion
- Nov 2022
- Modality
- Hormone, Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of estradiol in gender dysphoria (GD), sponsored by Medical College of Wisconsin. Primary endpoint: Coagulation system activation due to estradiol administration at 8 months. Started Dec 2021; status: terminated.
02
Drugs
estradiol
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on NCT05387577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387577.